David Nierengarten
Stock Analyst at Wedbush
(4.51)
# 322
Out of 5,182 analysts
233
Total ratings
57.21%
Success rate
19.2%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CATX Perspective Therapeutics | Reiterates: Outperform | $11 | $3.95 | +178.48% | 7 | Apr 20, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $53 → $58 | $53.85 | +7.71% | 7 | Apr 16, 2026 | |
| NVCR NovoCure | Reiterates: Neutral | $18 | $12.12 | +48.51% | 10 | Apr 16, 2026 | |
| NUVB Nuvation Bio | Reiterates: Outperform | $11 | $4.56 | +141.23% | 15 | Apr 16, 2026 | |
| FENC Fennec Pharmaceuticals | Reiterates: Outperform | $13 | $6.71 | +93.74% | 4 | Apr 16, 2026 | |
| SYRE Spyre Therapeutics | Maintains: Outperform | $65 → $80 | $68.63 | +16.57% | 2 | Apr 14, 2026 | |
| TLX Telix Pharmaceuticals | Reiterates: Outperform | $22 | $10.44 | +110.73% | 5 | Apr 13, 2026 | |
| NUVL Nuvalent | Reiterates: Outperform | $125 | $101.94 | +22.62% | 7 | Apr 8, 2026 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $20 → $17 | $9.65 | +76.17% | 11 | Apr 1, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Outperform | $56 → $58 | $46.73 | +24.12% | 8 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $21.92 | +36.86% | 4 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $55 | $36.34 | +51.35% | 5 | Mar 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $1,000 | $775.03 | +29.03% | 25 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $8 | $7.53 | +6.24% | 2 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $1.26 | +296.83% | 5 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $95 | $85.37 | +11.28% | 4 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $65 | $30.56 | +112.70% | 4 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $110 | $109.87 | +0.12% | 1 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $88 | $67.26 | +30.84% | 5 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $23.71 | +30.75% | 7 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $25 | $8.80 | +184.09% | 3 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $7 | $13.20 | -46.97% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $5 → $7 | $1.30 | +438.46% | 16 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $12.15 | +113.99% | 8 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $14.38 | -44.37% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $20 | $34.87 | -42.64% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $66.11 | -39.49% | 13 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $73.99 | -45.94% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $9.07 | +98.46% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.69 | +225.20% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $1.13 | +44,147.79% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $8.60 | +597.67% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $24.53 | +205.75% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.44 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.77 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $11.51 | - | 3 | Nov 20, 2017 |
Perspective Therapeutics
Apr 20, 2026
Reiterates: Outperform
Price Target: $11
Current: $3.95
Upside: +178.48%
Kiniksa Pharmaceuticals International,
Apr 16, 2026
Maintains: Outperform
Price Target: $53 → $58
Current: $53.85
Upside: +7.71%
NovoCure
Apr 16, 2026
Reiterates: Neutral
Price Target: $18
Current: $12.12
Upside: +48.51%
Nuvation Bio
Apr 16, 2026
Reiterates: Outperform
Price Target: $11
Current: $4.56
Upside: +141.23%
Fennec Pharmaceuticals
Apr 16, 2026
Reiterates: Outperform
Price Target: $13
Current: $6.71
Upside: +93.74%
Spyre Therapeutics
Apr 14, 2026
Maintains: Outperform
Price Target: $65 → $80
Current: $68.63
Upside: +16.57%
Telix Pharmaceuticals
Apr 13, 2026
Reiterates: Outperform
Price Target: $22
Current: $10.44
Upside: +110.73%
Nuvalent
Apr 8, 2026
Reiterates: Outperform
Price Target: $125
Current: $101.94
Upside: +22.62%
ORIC Pharmaceuticals
Apr 1, 2026
Maintains: Outperform
Price Target: $20 → $17
Current: $9.65
Upside: +76.17%
Scholar Rock Holding
Apr 1, 2026
Maintains: Outperform
Price Target: $56 → $58
Current: $46.73
Upside: +24.12%
Mar 31, 2026
Reiterates: Outperform
Price Target: $30
Current: $21.92
Upside: +36.86%
Mar 17, 2026
Reiterates: Outperform
Price Target: $55
Current: $36.34
Upside: +51.35%
Mar 9, 2026
Reiterates: Outperform
Price Target: $1,000
Current: $775.03
Upside: +29.03%
Mar 6, 2026
Maintains: Outperform
Price Target: $4 → $8
Current: $7.53
Upside: +6.24%
Mar 5, 2026
Maintains: Outperform
Price Target: $4 → $5
Current: $1.26
Upside: +296.83%
Mar 3, 2026
Maintains: Outperform
Price Target: $90 → $95
Current: $85.37
Upside: +11.28%
Feb 25, 2026
Maintains: Outperform
Price Target: $57 → $65
Current: $30.56
Upside: +112.70%
Feb 24, 2026
Initiates: Underperform
Price Target: $110
Current: $109.87
Upside: +0.12%
Feb 17, 2026
Maintains: Outperform
Price Target: $110 → $88
Current: $67.26
Upside: +30.84%
Jan 15, 2026
Reiterates: Outperform
Price Target: $31
Current: $23.71
Upside: +30.75%
Dec 11, 2025
Reiterates: Outperform
Price Target: $25
Current: $8.80
Upside: +184.09%
Nov 7, 2025
Maintains: Neutral
Price Target: $9 → $7
Current: $13.20
Upside: -46.97%
Oct 27, 2025
Upgrades: Outperform
Price Target: $5 → $7
Current: $1.30
Upside: +438.46%
Sep 2, 2025
Reiterates: Outperform
Price Target: $26
Current: $12.15
Upside: +113.99%
Jun 26, 2025
Reiterates: Neutral
Price Target: $8
Current: $14.38
Upside: -44.37%
Mar 14, 2025
Downgrades: Neutral
Price Target: $80 → $20
Current: $34.87
Upside: -42.64%
Feb 7, 2025
Maintains: Outperform
Price Target: $40
Current: $66.11
Upside: -39.49%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $73.99
Upside: -45.94%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $9.07
Upside: +98.46%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.69
Upside: +225.20%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $1.13
Upside: +44,147.79%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $8.60
Upside: +597.67%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $24.53
Upside: +205.75%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.44
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $3.77
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $11.51
Upside: -